Fresenius Medical Care AG
SWB:FME
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
F
|
Fresenius Medical Care AG
SWB:FME
|
DE |
|
Kirin Holdings Co Ltd
F:KIR
|
JP |
|
A
|
Ambev SA
SWB:AMNA
|
BR |
|
H
|
Honda Motor Co Ltd
SWB:HDMA
|
JP |
|
D
|
Dominion Energy Inc
XBER:DOD
|
US |
|
S
|
Sumitomo Realty & Development Co Ltd
XBER:RL2
|
JP |
|
S
|
Smoore International Holdings Ltd
OTC:SMORF
|
CN |
|
Sectra AB
STO:SECT B
|
SE |
|
Camtek Ltd
F:CMZ
|
IL |
|
Sekisui House Ltd
OTC:SKHSF
|
JP |
Fresenius Medical Care AG
Fresenius Medical Care AG is one of the world’s main kidney care companies. It treats patients with chronic kidney failure by running dialysis clinics and by providing dialysis treatments in hospitals and care centers. It also sells the equipment, filters, and related supplies needed to deliver dialysis, which makes it both a care provider and a medical products supplier. The company makes money in two main ways: from payments for dialysis treatments and from sales of dialysis machines, disposables, and other kidney care products. Its biggest customers are patients who need regular dialysis, along with hospitals, clinics, and healthcare systems that buy its products or contract for treatment services. This gives the business a steady connection to long-term, medically necessary care rather than one-off purchases. What makes the business model distinctive is that it sits on both sides of the dialysis market. Fresenius Medical Care not only treats patients, but also supplies many of the tools used in treatment, so it has direct exposure to the ongoing demand for kidney care from both service fees and product sales. That role gives it deep knowledge of dialysis workflows and a strong position in a specialized part of healthcare.
Fresenius Medical Care AG is one of the world’s main kidney care companies. It treats patients with chronic kidney failure by running dialysis clinics and by providing dialysis treatments in hospitals and care centers. It also sells the equipment, filters, and related supplies needed to deliver dialysis, which makes it both a care provider and a medical products supplier.
The company makes money in two main ways: from payments for dialysis treatments and from sales of dialysis machines, disposables, and other kidney care products. Its biggest customers are patients who need regular dialysis, along with hospitals, clinics, and healthcare systems that buy its products or contract for treatment services. This gives the business a steady connection to long-term, medically necessary care rather than one-off purchases.
What makes the business model distinctive is that it sits on both sides of the dialysis market. Fresenius Medical Care not only treats patients, but also supplies many of the tools used in treatment, so it has direct exposure to the ongoing demand for kidney care from both service fees and product sales. That role gives it deep knowledge of dialysis workflows and a strong position in a specialized part of healthcare.
Top line: Fresenius Medical Care said Q1 started well, with organic revenue up 4% and operating income up 10%, and it confirmed its full-year outlook.
Margin progress: Group operating margin improved 70 basis points to 10.1%, helped by FME25+ savings, stronger Care Delivery profitability, and solid performance in all three segments.
TDAPA explained: Management said Q1 included about EUR 80 million of TDAPA benefit, but a meaningful headwind is still expected in the second half of the year.
HDF rollout: The 5008X / HighVolumeHDF rollout is accelerating, with more than 100,000 treatments in early April and around 100 clinics converted; management said adoption and training are going well.
U.S. same-market growth: U.S. treatment growth was down 37 basis points, pressured by weather, lower referrals, insurance uncertainty tied to ACA subsidies, and elevated mortality, but the full-year view remains flat.
China pressure: Care Enablement continued to face pressure from volume-based procurement and tighter tender rules in China, although management still sees China as an attractive market long term.
Cash and balance sheet: Operating cash flow rose 39% and free cash flow rose 94% to EUR 40 million; the EUR 1 billion share buyback was completed early, and leverage stayed at 2.6x.
